Business
Publication of Annual Report & Notice of AGM
Publication of Annual Report & Notice of AGM.
About this update from Renalytix Plc
[{"type":"text","content":"\n\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nPublication of Annual Report 2025\n&\n Notice of 2025 Annual General Meeting\n \nLONDON and NEW YORK, 4 November 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that the Annual Report for the year ended 30 June 2025 and the Notice of 2025 Annual General Meeting (\"AGM\") have now been published on the Company's website and will be posted to shareholders who have not consented to receive electronic communications tomorrow morning.\n \nThe Annual report is available on the Company website here: https://investors.renalytix.com/annual-half-year-reports/\nThe full Notice of AGM can be found here: https://investors.renalytix.com/documents/\n \nThe AGM will be held in-person on 9 December 2025 at 10.00 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD. \n \nAny shareholder wishing to attend is required to register by contacting Walbrook PR via email at [email protected] or by telephone at +44 (0)20 7933 8780.\n \nFor further information, please contact:\n \n\n\n\n\nRenalytix plc\n\n\nwww.renalytix.com\n\n\n\n\nJames McCullough, CEO\n\n\nVia Walbrook PR\n\n\n\n\n\n\n\n\n\n\n\n\nSP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)\n\n\nTel: +44 (0)20 3470 0470\n\n\n\n\nJeff Keating / David Hignell (Corporate Finance)\nVadim Alexandre (Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOberon Capital (Joint Broker)\n\n\nTel: +44 (0)20 3179 5300\n\n\n\n\nMike Seabrook / Nick Lovering\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: 020 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Alice Woodings\n\n\nMob: 07980 541 893 / 07407 804 654\n\n\n\n\n\n\n\n\n\n \nAbout Renalytix (www.renalytix.com)\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.\n \nUnrecognized and uncontrolled kidney disease ...